# LinkBIO Co.

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/linkbio-co

- Industry: Pharmaceuticals
- Headquarters: Toride, Japan
- Website: https://linkbio.jp/
- Latest round: Seed (Oct 19, 2020)
- Investors on record: 1

## About

Based in Ibaraki, Japan, established in 2020, LinkBIO Co., Ltd. supports the development of new drugs, diagnostic drugs, reagents for regenerative medicine, etc. through joint or commissioned research and development. 
LinkBIO uses proprietary molecular separation technology developed by Prof. Yoshimoto of Tokyo University to carry out support for new drug discoveries which can provide great improvement of the visibility and concentration efficiency of the screening process (seed molecule) for the new drug candidate at the early stages. In particular, the company supplies nucleic acid aptamer (a molecule that binds to the target molecule) using the SELEX method or the MACE (Magnetic Assisted Capillary Electrophoresis Separation) method. 
Using aptamer is low-cost, allows screening at shorter periods of time, and does not degrade. 
Nucleic acid-based drugs can be created from chemical compounds, and is superior in terms of research and development speed, and safety of the product quality, compared to protein-based drugs such as antibodies, and producing them is relatively easy. Among which, Aptamer is being noticed because it has a special property of neutralizing drugs and makes it hard to induce immunization.

## Funding rounds

- Seed, Oct 19, 2020 — Samurai Incubate

## Investors

- Samurai Incubate (https://capitalatlas.ai/funds/samurai-incubate) — Seed